Dry pressed coating tablet containing tegafur, gimeracil and oteracil potassium

A technology of dry-pressed coated tablets and potassium oxonate, which is applied to medical preparations containing active ingredients, medical preparations with non-active ingredients, organic active ingredients, etc., can solve the problems of pharmaceutical exposure of medical workers, and achieve Tablet Strength Rapid, Reduced Exposure, Reduced Risk Effects

Inactive Publication Date: 2013-01-30
TAIHO PHARMA CO LTD
View PDF8 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, according to this patent, although the drug is a highly active anticancer agent, there is no countermeasure against pharmaceutical exposure of medical workers, caregivers, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry pressed coating tablet containing tegafur, gimeracil and oteracil potassium
  • Dry pressed coating tablet containing tegafur, gimeracil and oteracil potassium
  • Dry pressed coating tablet containing tegafur, gimeracil and oteracil potassium

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0065] Hereinafter, the present invention will be described in more detail with reference examples, working examples, and test examples, but the present invention is not limited to these examples. It should be noted that the tegafur and gimeracil used in this example were manufactured by Dapeng Pharmaceutical Industry Co., Ltd., and the potassium oxonate was manufactured by Sumitomo Chemical Industry Co., Ltd. In addition, hydroxypropyl cellulose (HPC) is made by Nippon Soda Co., partially α-starch and crystalline cellulose are made by Asahi Kasei Chemical Co., Ltd., magnesium stearate is made by Taiping Chemical Co., Ltd., and crospovidone is made by BASF Incorporated.

reference example 1

[0066] Reference Example 1 (Preparation of Core Component 1)

[0067] Using a fluidized bed granulator Multiplex MP-01 (manufactured by Powrex), in a mixture of 66.1 g of tegafur, 19.15 g of gimeracil, 64.75 g of potassium oxonate, and 150 g of lactose (manufactured by Borculo Domo Ingredients), 200.0 g of water was sprayed and granulated to prepare a core component.

reference example 2

[0068] Reference Example 2 (Preparation of Core Component 2)

[0069] By the same method as in Reference Example 1, in a mixture of 66.1 g of tegafur, 19.15 g of gemerazepam, 64.75 g of oxonate potassium, and 150 g of lactose (manufactured by Borculo Domo Ingredients Co., Ltd.), 199.0 g of water was dissolved with The liquid obtained by HPC 1.0 g was sprayed and granulated to prepare a core component.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention provides a dry pressed coating tablet which is composed of an inner core and an outer core, and the inner core contains (a)tegafur, (b) gimeracil and (c)oteracil potassium which can be taken as effective components.

Description

technical field [0001] The invention relates to an oral dry-pressed coated tablet containing Tegafur, Gimeracil and Oteracil potassium. Background technique [0002] Tegafur, gemeracil, and oxonate potassium compound is an antitumor agent, characterized in that: by compounding tegafur, which is a prodrug of fluorouracil (5-FU), as a decomposition inhibitor of 5-FU Gimeracil as a drug and potassium oxonate as a phosphorylation inhibitor can improve the anti-tumor effect and reduce the toxicity to digestive organs, and are widely used clinically as an oral tumor chemotherapy drug (Patent Document 1). [0003] At present, the content of Tegafur, Gimeracil and Potassium Oxonate in the molar ratio of Tegafur: Gimeracil: Potassium Oxonate is 1:0.4:1, and the "TS-1 Composite Capsule" Capsules are commercially available under the name of "TS-1 Compound Granules", and granules are commercially available under the name "TS-1 Compound Granules" (Patent Document 2). However, capsules ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/36A61K31/53A61K47/38A61K47/36A61K47/32A61P35/00A61K31/513A61K31/4412
Inventor 冈本拓己吉泽隆大西敬人
Owner TAIHO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap